Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1

Oncogene

Volumn 32, Issue 3, 2013, Pages 363-374

  Van Beijnum, J R ^a   Nowak Sliwinska, P ^a   Van Den Boezem, E ^b   Hautvast, P ^b   Buurman, W A ^c   Griffioen, A W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

autocrine; chicken embryo chorioallantoic membrane; high mobility group box 1; tumor angiogenesis; VEGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; PLATELET DERIVED GROWTH FACTOR; TOLL LIKE RECEPTOR 4; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL MOVEMENT; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; RECEPTORS, IMMUNOLOGIC;

EID: 84872615463     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.49     Document Type: Article

References (47)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 52: 237-268.
3. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
4. Thijssen VL, van Beijnum JR, Mayo KH, Griffioen AW. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr Pharm Des 2007; 13: 3576-3583.
5. van Beijnum JR, Griffioen AW. In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta 2005; 1755: 121-134.
6. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-2348.
7. van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW. Isolation of endothelial cells from fresh tissues. Nat Protoc 2008; 3: 1085-1091.
8. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989; 243 (4894 Part 1): 1056-1059.
9. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparinbinding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 1991; 266: 16722-16729.
10. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46.
11. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
12. Mitola S, Belleri M, Urbinati C, Coltrini D, Sparatore B, Pedrazzi M et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006; 176: 12-15.
13. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005; 166: 1259-1263.
14. Ohmori H, Luo Y, Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets 2011; 15: 183-193.
15. Tang D, Kang R, Zeh III HJ, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
16. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008; 11: 91-99.
17. Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer 2010; 46: 3007-3015.
18. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25: 23-31.
19. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38.
20. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72: 1084-1091.
21. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
22. Mullins GE, Sunden-Cullberg J, Johansson AS, Rouhiainen A, Erlandsson-Harris H, Yang H et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol 2004; 60: 566-573.
23. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-2660.
24. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375-385.
25. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME et al. Redox modification of cysteine residues regulates the cytokine activity of HMGB1. Mol Med (e-pub ahead of print 7 November 2011; doi:10.2119/molmed. 2011.00389).
26. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996; 88: 667-673.
27. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761.
28. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377.
29. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999; 274: 19919-19924.
30. Youn JH, Shin JS. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177: 7889-7897.
31. Oh YJ, Youn JH, Ji Y, Lee SE, Lim KJ, Choi JE et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 2009; 182: 5800-5809.
32. Hagedorn M, Javerzat S, Gilges D, Meyre A, de Lafarge B, Eichmann A et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 1643-1648.
33. Nowak-Sliwinska P, Ballini JP, Wagnieres G, van den Bergh H. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc Res 2010; 79: 21-28.
34. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, van den Bergh H, Griffioen AW. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010; 13: 281-292.
35. Agresti A, Lupo R, Bianchi ME, Muller S. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun 2003; 302: 421-426.
36. Kawahara K, Biswas KK, Unoshima M, Ito T, Kikuchi K, Morimoto Y et al. C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 2008; 17: 129-138.
37. Zhang CL, Shu MG, Qi HW, Li LW. Inhibition of tumor angiogenesis by HMGB1 A box peptide. Med Hypotheses 2008; 70: 343-345.
38. Li W, Sama AE, Wang H. Role of HMGB1 in cardiovascular diseases. Curr Opin Pharmacol 2006; 6: 130-135.
39. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
40. Biscetti F, Straface G, De Cristofaro R, Lancellotti S, Rizzo P, Arena V et al. High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes 2010; 59: 1496-1505.
41. Fontijn R, Hop C, Brinkman HJ, Slater R, Westerveld A, van Mourik JA et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 1995; 216: 199-207.
42. van Beijnum JR, van der Linden E, Griffioen AW. Angiogenic profiling and comparison of immortalized endothelial cells for functional genomics. Exp Cell Res 2008; 314: 264-272.
43. Nowak-Sliwinska P, van Beijnum JR, Casini A, Nazarov AA, Wagnieres G, van den Bergh H et al. Organometallic ruthenium(II) arene compounds with antiangiogenic activity. J Med Chem 2011; 54: 3895-3902.
44. Lim SH, Thivierge C, Nowak-Sliwinska P, Han J, van den Bergh H, Wagnieres G et al. In vitro and in vivo photocytotoxicity of boron dipyrromethene derivatives for photodynamic therapy. J Med Chem 2010; 53: 2865-2874.
45. Laib AM, Bartol A, Alajati A, Korff T, Weber H, Augustin HG. Spheroidbased human endothelial cell microvessel formation in vivo. Nat Protoc 2009; 4: 1202-1215.
46. Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TJ, Ballini JP, Lovisa B et al. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J Cell Mol Med (e-pub ahead of print 1 September 2011; doi:10.1111/j.1582-4934. 2011. 01440.x).
47. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004; 299: 286-293.